49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-004635-29-DK (EUCTR) | 09/11/2007 | 02/10/2007 | Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 | Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 | Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study. | Product Name: ASF-1096 Cream 0.25% INN or Proposed INN: R-salbutamol sulphate Product Name: ASF-1096 Cream 0.5% INN or Proposed INN: R-salbutamol sulphate Product Name: ASF-1096 Cream 1.0% INN or Proposed INN: R-salbutamol sulphate | Astion Pharma A/S | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Denmark;Spain;Sweden | |||
| 2 | EUCTR2007-004635-29-SE (EUCTR) | 07/11/2007 | 12/09/2007 | Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 | Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 | Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study. | Product Name: ASF-1096 Cream 0.25% INN or Proposed INN: R-salbutamol sulphate Product Name: ASF-1096 Cream 0.5% INN or Proposed INN: R-salbutamol sulphate Product Name: ASF-1096 Cream 1.0% INN or Proposed INN: R-salbutamol sulphate | Astion Pharma A/S | NULL | Not Recruiting | Female: yes Male: yes | 140 | Denmark;Spain;Sweden | |||
| 3 | EUCTR2006-001062-17-SE (EUCTR) | 07/03/2007 | 12/01/2007 | Efficacy and safety of ASF-1096 Cream 0.5% in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multi centre clinical phase 2, placebo controlled and double blind proof of concept study. - Lupus study | Efficacy and safety of ASF-1096 Cream 0.5% in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multi centre clinical phase 2, placebo controlled and double blind proof of concept study. - Lupus study | Male or female patients with a clinical diagnosis of either Discoid Lupus Erythematosus or Systemic Lupus Erythematosus and at least one newly developed, sharply demarcated DLE lesion. MedDRA version: 8.1;Level: LLT;Classification code 10025138;Term: | Product Name: ASF-1096 Cream 0.5% | Astion Danmark A/S | NULL | Not Recruiting | Female: yes Male: yes | 52 | Phase 2 | United Kingdom;Sweden |